The Analysis Of Clinical Efficacy On Autologous Perpheral Blood Stem Transpaltation Of 45 Patients With Acute Myeloid Leukemia

Objective: The goal of the retrospective study was to investigate the clinical efficacy of autologous peripheral blood stem cell transplantation in the treatment of acute myeloid leukemia.Methods: A retrospective analysis of 45 patients with AML who received APBSCT in the First Affiliated Hospital of Guangxi Medical University from September 2004 to September 2017.Some transplant related indicators,such as hematopoietic reconstitution time,disease-free survival(DFS),overall survival(OS),and recurrence rate(RR)were analyzed.Results: Among 45 AML patients,24 males,and 21 females,the median age at transplant was 37 years(16-60 years).The median follow-up time was 24months(2-157 months).Two patients relapsed before hematopoietic reconstruction,other 43 patients received hematopoietic reconstruction.The median time for neutrophil reconstruction was +10(+6-+26)days,and the median time for platelet reconstruction was +13(+6-+180)days.3 patients(7.6%)were lost from follow-up.The 3-year and 5-year DFS rates were both63.1%,and the 3-year and 5-year OS rates were 67.7% and 60.4%,respectively.The cumulative rate of recurrence(RR)for 1 year,3 years,5 years were 21.6%,36.9% and 36.9%,respectively.Univariate analysis showed that the age of patients was a factor that influenced the prognosis.The OS and DFS of patients aged <40 years were better than those of patients age? 40 years.Multivariate analysis showed that the age of AML was an independent prognostic factor for DFS.Conclusions: APBSCT is effective for AML.Some AML patients can obtain long-term survival.